In myeloid cells, ITGA4 activation leads to tumour inflammation and growth, whereas natalizumab, a recombinant humanized anti‐ITGA4 antibody, decreases myeloma growth by blocking the interaction between myeloma cells and bone marrow stromal cells 41. Here, ITGA4 is linked to neoplasm.